Effect of a pharmaceutical care program on vascular risk factors in type 2 diabetes: The Fremantle Diabetes Study

Diabetes Care

Volumn 28, Issue 4, 2005, Pages 771-776

  Clifford, Rhonda M ^a,b   Davis, Wendy A ^b   Batty, Kevin T ^a   Davis, Timothy M E ^b,c  

^a CURTIN UNIVERSITY   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c FREMANTLE HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INSULIN; ORAL ANTIDIABETIC AGENT;

ADULT; AGED; ARTICLE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CONTROLLED STUDY; COUNSELING; DEMOGRAPHY; DIASTOLIC BLOOD PRESSURE; FEMALE; GLUCOSE BLOOD LEVEL; HEALTH CARE; HEALTH PROGRAM; HUMAN; INSULIN TREATMENT; ISCHEMIC HEART DISEASE; LIFESTYLE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOMES RESEARCH; PATIENT EDUCATION; PHARMACEUTICAL CARE; PHYSICIAN; RISK FACTOR; STROKE; SYSTOLIC BLOOD PRESSURE;

ADMINISTRATION, ORAL; AGED; AUSTRALIA; BLOOD PRESSURE; BODY MASS INDEX; CHOLESTEROL; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; PATIENT EDUCATION; RISK ASSESSMENT; TRIGLYCERIDES;

EID: 15944406491     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.28.4.771     Document Type: Article

References (32)

1. UK Prospective Diabetes Study (UKPDS) Group: Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837-853, 1998
2. UK Prospective Diabetes Study Group: Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 317:703-713, 1998
3. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators: Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 355:253-259, 2000
4. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O: Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 348:383-393, 2000
5. Viberti G: The need for tighter control of cardiovascular risk factors in diabetic patients. J Hypertens 21 (Suppl. 1):S3-S6, 2003
6. Hepler C, Strand L: Opportunities and responsibilities in pharmaceutical care. Am J Hosp Pharm 47:533-543, 1990
7. Kennie NR, Schuster BG, Einarson TR: Critical analysis of the pharmaceutical care research literature. Ann Pharmacother 32:17-26, 1998
8. Jaber LA, Halapy H, Fernet M, Tummalapalli S, Diwakaran H: Evaluation of a pharmaceutical care model on diabetes management. Ann Pharmacother 30:238-243, 1996
9. Coast-Senior EA, Kroner BA, Kelley CL, Trilli LE: Management of patients with type 2 diabetes by pharmacists in primary care clinics. Ann Pharmacother 32:636-641, 1998
10. Sczupak CA, Conrad WF: Relationship between patient-oriented pharmaceutical services and therapeutic outcomes of ambulatory patients with diabetes mellitus. Am J Hosp Pharm 34:1238-1242, 1977
11. Cooper J: Consultant pharmacist contribution to diabetes mellitus patients outcomes in two nursing facilities. Consult Pharm 10:40-45, 1995
12. Baran RW, Crumlish K, Patterson H, Shaw J, Erwin WG, Wylie JD, Duong P: Improving outcomes of community-dwelling older patients with diabetes through pharmacist counselling. Am J Health Syst Pharm 56:1535-1539, 1999
13. Cranor CW, Bunting BA, Christensen DB: The Asheville project: long-term clinical and economic outcomes of a community pharmacy diabetes care program. J Am Pharm Assoc 43:173-184, 2003
14. Clifford RM, Batty KT, Davis TM, Davis W, Stein G, Stewart G, Plumridge RJ: A randomised controlled trial of a pharmaceutical care programme in high-risk diabetic patients in an outpatient clinic. Int J Pharm Pract 10:85-89, 2002
15. Irons BK, Lenz RJ, Anderson SL, Wharton B, Habeger B, Anderson G: A retrospective cohort analysis of the clinical effectiveness of a physician-pharmacist collaborative drug therapy management diabetes clinic. Pharmacotherapy 22:1294-1300, 2002
16. Wagner EH, Grothaus LC, Sandhu N, Galvin MS, McGregor M, Artz K: Chronic care clinics for diabetes in primary care. Diabetes Care 25:695-700, 2001
17. Tully MP, Seston EM: Impact of pharmacists providing a prescription review and monitoring service in ambulatory care or community practice. Ann Pharmacother 34:1320-1331, 2000
18. Davis TME, Zimmet P, Davis WA, Bruce D, Fida S, Mackay I: Autoantibodies to glutamic acid decarboxylase in diabetic patients from a multi-ethnic Australian community: the Fremantle Diabetes Study. Diabet Med 17:667-674, 2000
19. Bruce DG, Davis WA, Davis TME: Glycemic control in elderly subjects with type 2 diabetes mellitus in the Fremantle Diabetes Study. J Am Geriatr Soc 48:1449-1453, 2000
20. Davis TME, Fortun P, Mulder J, Davis WA, Bruce DG: Silent myocardial infarction and its prognosis in a community-based cohort of type 2 diabetic patients: the Fremantle Diabetes Study. Diabetologia 47:395-399, 2004
21. Gillett M, Davis WA, Jackson D, Bruce DG, Davis TME: Prospective evaluation of carotid bruit as a predictor of first stroke in type 2 diabetes: the Fremantle Diabetes Study. Stroke 34:2145-2151, 2003
22. Australian Government Department of Health and Ageing: Schedule of Pharmaceutical Benefits for Approved Pharmacists and Medical Practitioners. Canberra, Australia, Commonwealth of Australia, 2004, p. 176
23. Healthy eating and activity guide [article online], 2004. Available from http://www. heartfoundation.com.au/downloads/HE_ PA_guide_04.pdf. Accessed 20 December 2004
24. Stevens RJ, Kothari V, Adler AI, Stratton IM, the United Kingdom Prospective Diabetes Study (UKPDS) Group: The UKPDS risk engine: a model for the risk of coronary heart disease in type II diabetes (UKPDS 56). Clin Sci 101:671-679, 2001
25. Kothari V, Stevens RJ, Adler AI, Stratton IM, Manley SE, Neil HA, Holman RR: UKPDS 60: risk of stroke in type 2 diabetes estimated by the UK Prospective Diabetes Study risk engine. Stroke 33:1776-1781, 2002
26. Stratton IM, Alder AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR: Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 321:405-412, 2000
27. Adler AI, Stratton IM, Neil HA, Yudkin JS, Matthew DR, Cull CA, Wright DA, Turner RC, Holman RR: Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ 321:412-419, 2000
28. Working Party of the International Diabetes Federation (European Region): Hypertension in people with Type 2 diabetes: knowledge-based diabetes-specific guidelines. Diabet Med 20:972-987, 2003
29. American Diabetes Association: Aspirin therapy in diabetes (Position Statement). Diabetes Care 26 (Suppl. 1):S87-S88, 2003
30. Farris KB, Kirking DM: Assessing the quality of pharmaceutical care. I. One perspective of quality. Ann Pharmacother 27:68-73, 1993
31. Farris KB, Kirking DM: Assessing the quality of pharmaceutical care. II. Application of concepts of quality assessment from medical care. Ann Pharmacother 27:215-223, 1993
32. Bruce D, Davis WA, Cull CA, Davis TME: Diabetes education and knowledge in patients with type 2 diabetes from the community: the Fremantle Diabetes Study. J Diabetes Complications 7:82-89, 2003